CD38 CAR T / DAR T

CD38 CAR T and DAR T are our product candidates for the treatment of Multiple Myeloma

  • Second most common blood cancer
  • Despite increased availability of novel agents, the disease is characterized by a pattern of recurrent relapses and remains incurable for the majority of patients
  • Approximately 80,000 deaths per year worldwide
  • 114,000 new cases diagnosed globally per year
  • The plasma cells are a type of white blood cell in the bone marrow. With this condition, a group of plasma cells becomes cancerous and multiplies
  • The disease can damage the bones, immune system, kidneys and red blood cell count
  • Treatments include medications, chemotherapy, corticosteroids, radiation or a stem-cell transplant
  • People may experience pain in the back or bones, anemia, fatigue, constipation, hypercalcemia, kidney damage or weight loss
Cancerous plasma cells weaken bones leading to fracture
Multiple Myeloma
  • Second most common blood cancer
  • Despite increased availability of novel agents, the disease is characterized by a pattern of recurrent relapses and remains incurable for the majority of patients
  • Approximately 80,000 deaths per year, worldwide
  • 114,000 new cases diagnosed globally per year
  • The plasma cells are a type of white blood cell in the bone marrow. With this condition, a group of plasma cells becomes cancerous and multiplies
  • The disease can damage the bones, immune system, kidneys, and red blood cell count
  • Treatments include medications, chemotherapy, corticosteroids, radiation, or a stem-cell transplant
  • People may experience pain in the back or bones, anemia, fatigue, constipation, hypercalcemia, kidney damage, or weight loss

bone-fracture2

Cancerous plasma cells weaken bones leading to fracture

Multiple Myeloma